Brand name product starts from 62.50 USD/tablet

No generic equivalent available

Marketed as Jakafi in US and Canada, Marketed as Jakavi in Europe and UK

Related Names: Ruxolitinib Tablets

Active Substance: Ruxolitinib

Brand Name Manufactured by: Novartis

Generic Equivalent Manufactured by: Various Generic Manufacturers

WHAT JAKAVI IS AND WHAT IT IS USED FOR

Jakavi is used to treat adult patients with an enlarged spleen or with symptoms related to myelofibrosis, a rare form of blood cancer.

Jakavi is also used to treat adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.

Jakavi is also used to treat:
- children aged 28 days and older and adults with acute graft versus host disease (GvHD).
- children aged 6 months and older and adults with chronic GvHD.
There are two forms of GvHD: an early form called acute GvHD that usually develops soon after the transplantation and can affect skin, liver and gastrointestinal tract, and a form called chronic GvHD, which develops later, usually weeks to months after the transplantation. Almost any organ can be affected by chronic GvHD.

How Jakavi works
Enlargement of the spleen is one of the characteristics of myelofibrosis. Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue. The abnormal marrow can no longer produce enough normal blood cells and as a result the spleen becomes significantly enlarged. By blocking the action of certain enzymes (called Janus Associated Kinases), Jakavi can reduce the size of the spleen in patients with myelofibrosis and relieve symptoms such as fever, night sweats, bone pain and weight loss in patients with myelofibrosis. Jakavi can help reduce the risk of serious blood or vascular complications.

Polycythaemia vera is a disorder of the bone marrow, in which the marrow produce too many red blood cells. The blood becomes thicker as a result of the increased red blood cells. Jakavi can relieve the symptoms, reduce spleen size and the volume of red blood cells produced in patients with polycythaemia vera by selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), thus potentially reducing the risk of serious blood or vascular complications.

Graft versus host disease is a complication which occurs after transplantation when specific cells (T cells) in the donor’s graft (e.g. bone marrow) do not recognise the host cells/organs and attack them. By selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), Jakavi reduces signs and symptoms of the acute and the chronic forms of graft-versus-host disease leading to disease improvement and survival of the transplanted cells.

If you have any questions about how Jakavi works or why this medicine has been prescribed for you, ask your doctor.

Buy brand name or generic Jakavi (Ruxolitinib) from World Medicine Store Online Pharmacy at reasonable price. World Medicine Store ships discount Jakavi (Ruxolitinib) and other prescription drugs worldwide.

If you have any question about how to order cheap Jakavi (Ruxolitinib) online or any other prescription medicines, please contact with our pharmacists. If you have any question about how to take it or if you need dosage information about it or any other prescription medicines, please talk to your doctor.